Coca Cola & Pepsi Co., in tandem with five other beverage firms give the green light to lower sugar content in Singapore drinks
Category: #retail  By Saipriya Iyer  Date: 2017-08-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Coca Cola & Pepsi Co., in tandem with five other beverage firms give the green light to lower sugar content in Singapore drinks

The health campaign in Singapore with regards to limiting diabetes in the city has recently hit a new high with seven leading beverage companies including the likes of Pepsi Co. and Coca Cola, having taken a pledge to bring down the sugar content in their manufactured drinks commercially sold in Singapore. Reportedly, five other companies including Nestlé, Yeo Hiap Seng, F&N Foods, Pokka, and Malaysia Dairy Industries have also committed to cap the sugar proportion of their sweetened drinks up to 12% by 2020, as confirmed by the Ministry of Health of Singapore. Undoubtedly, state experts, this is one of the most appreciable pacts to have taken place in food and beverage industry in recent times.

The pledge is reported to be the first of its kind in the Asian Countries when a national health organization has witnessed such a commitment from some of the largest beverage producers in the industry. Singapore is reported to be one of the first countries to target sugary drinks. The agreement to curb sugar content in drinks that would be sold in Singapore follows the lines of the efforts undertaken by the Western Governments that target the elimination of obesity. Having said that, worldwide, beverage companies have been increasingly focusing on health-related recipes, with an aim to bring forth healthier products having lower sugar content.

In concurrence with the unanimous commitment, Coca Cola has taken an additional pledge to limit the sugar content in its current beverage portfolio by 10% by 2020. It has been also stated by the carbonated soft drink maker that they have started endorsing low sugar content drinks with no added sugar for many of their brands.

Statistics claim that the per capita sugar consumption from soft drinks in the APAC belt has increased to 6.08 grams from 2010 to 2016, with Singapore consuming almost 11.99 grams. Though it has been observed that the consumption trend is lower in the European countries and U.S., it is relatively higher than the APAC region. Asian governments of late, have been increasingly focusing on healthy consumption, as is evident from their strong pipeline of projects in the food and beverage products market. A recent instance of this is that of Malaysia launching the Healthier Choices Logo in April. It now remains to be seen how this multi-firm pledge will impact the beverage industry and consumer health in Singapore.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Montero inks agreement to acquire Isabella Gold Silver Project
Montero inks agreement to acquire Isabella Gold Silver Project
By Saipriya Iyer

Montero Mining and Exploration Ltd. has reportedly inked a Binding Purchase & Sale Agreement to acquire a 100% or full interest in a private company in Chile. ChileCo holds several mineral rights to exploration cla...

PharmaCyte to submit IND application to FDA for clinical trial in LAPC
PharmaCyte to submit IND application to FDA for clinical trial in LAPC
By Saipriya Iyer

PharmaCyte Biotech, a clinical-stage biotechnology company, is reportedly set to submit an IND (Investigational New Drug) application to the U.S. FDA. The IND application is related to the Phase 2b clinical trial among...

Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
By Saipriya Iyer

Immunic, Inc. has recently announced positive topline results from the Phase 2 EMPhASIS trial of IMU-838, in patients with RRMS (relapsing-remitting multiple sclerosis). IMU-838 is a next-generation, orally available s...